DBDirk-Jan van Beek

Dirk-Jan van Beek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dirk-Jan van Beek has a total of 142 co-authors. Here are the top co-authors by number of shared publications:

  • Menno R. Vriens

    Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

    8 shared publications
  • Gerlof Dirk Valk

    Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, Netherlands

    6 shared publications
  • Gerlof D. Valk

    Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

    5 shared publications
  • Inne H.M. Borel Rinkes

    Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands

    4 shared publications
  • Inne H. M. Borel Rinkes

    Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

    3 shared publications
  • Rachel S van Leeuwaarde

    Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

    3 shared publications

Latest Publications

  • Open Access

    Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A

    by Marijn L van Den Berg, Dirk-Jan van Beek, Medard F M van Den Broek, Lutske Lodewijk, Annemarie A Verrijn Stuart, Sheila C E J Terwisscha van Scheltinga, Rachel S van Leeuwaarde, Inne H M Borel Rinkes, Menno R Vriens

    Thyroidectomy is recommended for patients with multiple endocrine neoplasia type 2A (MEN2A). American Thyroid Association 2015 guidelines recommend follow-up of calcitonin values after thyroidectomy. The aim of this study was to determine the natural course of calcitonin levels after total thyroidectomy (TTx) in MEN2A patients. Patients with MEN2A who underwent TTx between 1993 and 2019 and had multiple postoperative calcitonin measurements were retrospectively included from our referral center. Long-term serial calcitonin measurements and clinical outcomes were correlated to the first postoperative calcitonin, histopathology and type of TTx (prophylactic versus non-prophylactic). Fifty-two patients underwent TTx after 1993 at a median age of 10 years (range 0–71). Of these, 23 (44%) had no MTC and 29 (56%) had MTC. The median follow-up time was 12 years (range 3–30). Thirty-eight patients had an ‘undetectable’ first postoperative calcitonin, seven ‘within reference range’ and seven ‘above reference range’. Of the 38 patients with an ‘undetectable’ first postoperative calcitonin, 32 remained ‘undetectable’. All 21 patients without MTC and ‘undetectable’ first postoperative calcitonin remained ‘undetectable’. Of the 17 patients with MTC and ‘undetectable’ first postoperative calcitonin, 11 remained ‘undetectable’ and none developed structural recurrence. Twenty-two of the 25 patients undergoing prophylactic thyroidectomy had repeated ‘undetectable’ measurements. Persistent MTC or structural recurrence occurred in six patients; all had MTC, had a detectable first postoperative calcitonin and underwent non-prophylactic TTx. In conclusion, the long-term serial calcitonin values remain undetectable in the majority of the patients with an undetectable first postoperative calcitonin. Biochemical follow-up for patients without MTC and an undetectable first postoperative calcitonin may not be necessary.


  • Surgery for advanced neuroendocrine tumours of the small bowel: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES)

    by Klaas Van Den Heede, Dirk-Jan van Beek, Sam Van Slycke, Inne Borel Rinkes, Olov Norlén, Peter Stålberg, Erik Nordenström

    Background: Small bowel neuroendocrine tumours often present with locally advanced or metastatic disease. The aim of this paper is to provide evidence-based recommendations regarding (controversial) topics in the surgical management of advanced small bowel neuroendocrine tumours. Methods: A working group of experts was formed by the European Society of Endocrine Surgeons. The group addressed 11 clinically relevant questions regarding surgery for advanced disease, including the benefit of primary tumour resection, the role of cytoreduction, the extent of lymph node clearance, and the management of an unknown primary tumour. A systematic literature search was performed in MEDLINE to identify papers addressing the research questions. Final recommendations were presented and voted upon by European Society of Endocrine Surgeons members at the European Society of Endocrine Surgeons Conference in Mainz in 2023. Results: The literature review yielded 1223 papers, of which 84 were included. There were no randomized controlled trials to address any of the research questions and therefore conclusions were based on the available case series, cohort studies, and systematic reviews/meta-analyses of the available non-randomized studies. The proposed recommendations were scored by 38–51 members and rated ‘strongly agree’ or ‘agree’ by 64–96% of participants. Conclusion: This paper provides recommendations based on the best available evidence and expert opinion on the surgical management of locally advanced and metastatic small bowel neuroendocrine tumours.


  • Open Access

    Surgery for advanced pancreatic neuroendocrine neoplasms: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES)

    by Dirk-Jan Van Beek, Klaas Van Den Heede, Inne Borel Rinkes, Olov Norlén, Sam Van Slycke, Peter Stålberg, Erik Nordenström

    Pancreatic neuroendocrine neoplasms (pNEN) comprise less than 5% of all pancreatic neoplasms. Despite their rarity, the incidence has steadily increased in both the USA and Europe over recent decades1,2. In Europe, their age-standardized incidence reached 1 per 100 000 inhabitants in 2018 and an average annual increase of 110.6% was observed2. pNEN represent a heterogeneous group of tumours, including functioning tumours secreting hormones that lead to distinct clinical syndromes, as well as non-functioning tumours with an inherent malignancy risk. pNEN are stratified into pancreatic neuroendocrine tumours (pNET) (grade 1 (G1), grade 2 (G2), and grade 3 (G3)) and pancreatic neuroendocrine carcinoma (pNEC) according to the WHO classification system3,4. The WHO 2017 classification further subdivided G3 tumours into pNET (G3) and pNEC because of genetic, clinical, histological, and prognostic differences that affect subsequent treatment3,5.


  • Open Access

    Assessing Outcomes After Adrenalectomy for Primary Aldosteronism – Early is Accurate

    by Diederik P.D. Suurd, Wessel M.C.M. Vorselaars, Dirk-Jan Van Beek, Inne. H.M. Borel Rinkes, Wilko Spiering, Gerlof D. Valk, Menno R. Vriens

    Objective: We aimed to investigate the postoperative trend in blood pressure (BP)-related outcomes [BP and antihypertensive (AHT) drug use] during the year following adrenalectomy for primary aldosteronism (PA) to determine the optimal timing for outcome assessment and to determine the necessary follow-up length. Background: Since the course of BP-related outcomes after adrenalectomy is unknown, the optimal timing of outcome assessment and follow-up duration are not clear. Methods: In this retrospective single center cohort study, we used a prospectively collected database with all patients referred for difficult-to-control-hypertension-analysis. All patients diagnosed with PA who underwent adrenalectomy were included. AHT drug use [in defined daily dose (DDD)] and home blood pressure measurements (HBPMs) during the first postoperative year were collected. A mixed-effects model was developed to assess the stability of DDD and HBPM over time and adjust for potential confounders. Results: In total 1784 patients were assessed for difficult-to-control-hypertension of whom 41 were included. Both the DDD and HBPM showed the strongest decrease in the first postoperative month (mean 1.6DDD; mean 140/85 mm Hg) compared with preoperative values (4.5DDD; 153/92 mm Hg). Thereafter, both outcomes showed a stable course from 4 to 6 months (1.6DDD; 136/86 mm Hg) up to 12 months postoperatively (2.0DDD; 136/83 mm Hg). Conclusions: This study showed that AHT drug use and HBPM decreased substantially within the first month after adrenalectomy for PA and afterwards generally remained stable during the year following adrenalectomy. We propose that BP-related outcomes can be assessed reliably early after adrenalectomy and question the need for routine long-term follow-up in referral centers.


  • Open Access

    Risk factors for complications after surgery for pancreatic neuroendocrine tumors

    by Dirk-Jan van Beek, Tim J. Takkenkamp, Edgar M. Wong-Lun-Hing, Ruben H.J. de Kleine, Annemiek M.E. Walenkamp, Joost M. Klaase, Maarten W. Nijkamp, Gerlof D. Valk, I. Quintus Molenaar, Jeroen Hagendoorn, et al.


  • Open Access

    Use of intraoperative parathyroid hormone measurements during parathyroidectomy to predict postoperative parathyroid hormone levels in patients with renal hyperparathyroidism: meta-analysis

    by Dirk-Jan van Beek, Stina Fredriksson, Stefanie Haegele, Marco Raffaelli, Philipp Riss, Martin Almquist

    Background: Several studies have reported on the use of intraoperative parathyroid hormone (ioPTH) measurements during parathyroidectomy (PTX) for renal hyperparathyroidism (rHPT), but there is no consensus on whether it is helpful and, if so, what protocol should be used. Therefore, the literature was systematically reviewed to assess a correlation between ioPTH and early postoperative parathyroid hormone (PTH) levels in patients undergoing PTX for rHPT, separately for those on dialysis and those with a functioning renal transplant. Methods: A systematic literature search was performed in electronic databases. Quality assessment was performed using the Quality In Prognosis Studies tool. Mean ioPTH values were calculated at different time points and correlated to the postoperative PTH levels within 1 month. Fixed-effect and random-effects models were performed to assess the mean ioPTH levels at 10 or 20 min after resection (T10 and T20). Stratified analyses were performed for patients on dialysis and those with a functioning renal transplant. Results: Of the 3087 records screened, 14 studies were included, including some 1177 patients; 1091 were on dialysis and 86 had a functioning kidney transplant. Risk of bias was moderate for most studies. For patients on dialysis, T10 and T20 mean ioPTH levels were 32.1 (95 per cent c.i. 24.3 to 39.9) pmol/l and 15.4 (95 per cent c.i. 7.8 to 22.9) pmol/l) in the random effects meta-analysis. Between individual studies, ioPTH ranged from 4.0–65.1 pmol/l at T10 and 8.6–25.7 pmol/l at T20. T10 and T20 ioPTH were 9.6 and 4.1 times the postoperative PTH—after T20 ioPTH stabilized in those on dialysis. In patients with a functioning renal transplant, ioPTH levels seemed to plateau after 10 min and measured 2.6 times the postoperative PTH. Conclusion: There is a strong correlation between ioPTH and early postoperative PTH levels, indicating that ioPTH is potentially a useful instrument during PTX in patients with rHPT. For patients on dialysis, at T20 ioPTH levels have stabilized and are approximately four times the postoperative PTH. Therefore, it is recommended to use ioPTH 20 min after resection in patients on dialysis, which might be longer than necessary for those with a kidney transplant.


  • Open Access

    Trends in blood pressure-related outcomes after adrenalectomy in patients with primary aldosteronism: A systematic review

    by Diederik P.D. Suurd, Wessel M.C.M. Vorselaars, Dirk-Jan Van Beek, Wilko Spiering, Inne H.M. Borel Rinkes, Gerlof D. Valk, Menno R. Vriens


  • Open Access

    Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort

    by Dirk-Jan van Beek, Sjoerd Nell, Wessel M. C. M. Vorselaars, Bert A. Bonsing, Casper H. J. van Eijck, Harry van Goor, Elisabeth J. Nieveen van Dijkum, Cornelis H. C. Dejong, Gerlof D. Valk, the DutchMEN Study Group (DMSG), et al.

    Background: Little is known about complications after major duodenopancreatic surgery for duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). Therefore, the incidence and severity of complications after major surgery for MEN1-related dpNETs were assessed. Methods: Patients were selected from the population-based Dutch MEN1 database if they had undergone a Whipple procedure or total pancreatectomy from 2003 to 2017. Complications were graded according to the Clavien–Dindo classification (grade III or higher complications were considered a severe complication) and definitions from the International Study Group of Pancreatic Surgery. The Cumulative Complication Index (CCI®) was calculated as the sum of all complications weighted for their severity. Univariable logistic regression was performed to assess potential associations between predictor candidates and a severe complication. Results: Twenty-seven patients (median age 43 years) underwent a major duodenopancreatic resection, including 14 Whipple procedures and 13 total pancreatectomies. Morbidity and mortality were 100% (27/27) and 4% (1/27), respectively. A severe complication occurred in 17/27 (63%) patients. The median CCI® was 47.8 [range 8.7–100]. Grade B/C pancreatic fistulas, delayed gastric emptying, bile leakage, hemorrhage, and chyle leakage occurred in 7/14 (50%), 10/27 (37%), 1/27 (4%), 7/27 (26%), 3/27 (11%) patients, respectively. Patients with a severe complication had longer operative time and higher blood loss. After Whipple, new-onset endocrine and exocrine insufficiency occurred in 1/13 and 9/14 patients, respectively. Conclusions: Major duodenopancreatic surgery in MEN1 is associated with a very high risk of severe complications and cumulative burden of complications and should therefore be reserved for a select subgroup of patients with MEN1-related dpNETs.


  • Genetic variability of immune‐related lncRNAs: polymorphisms in LINC‐PINT and LY86‐AS1 are associated with pemphigus foliaceus susceptibility

    by Amanda Salviano‐Silva, Ticiana Della Justina Farias, Valéria Bumiller‐Bini, Mariana de Sousa Castro, Sara Cristina Lobo‐Alves, Hauke Busch, Claudia Pföhler, Margitta Worm, Matthias Goebeler, Nina van Beek, et al.

    Pemphigus foliaceus (PF) is an autoimmune blistering disease of the skin, clinically characterized by erosions and, histopathologically, by acantholysis. PF is endemic in the Brazilian Central‐Western region. Numerous single nucleotide polymorphisms (SNPs) have been shown to affect the susceptibility for PF, including SNPs at long non‐coding RNA (lncRNA) genes, which are known to participate in many physiological and pathogenic processes, such as autoimmunity. Here, we investigated whether the genetic variation of immune‐related lncRNA genes affects the risk for endemic and sporadic forms of PF. We analysed 692 novel SNPs for PF from 135 immune‐related lncRNA genes in 227 endemic PF patients and 194 controls. The SNPs were genotyped by Illumina microarray and analysed by applying logistic regression at additive model, with correction for sex and population structure. Six associated SNPs were also evaluated in an independent German cohort of 76 sporadic PF patients and 150 controls. Further, we measured the expression levels of two associated lncRNA genes (LINC‐PINT and LY86‐AS1) by quantitative PCR, stratified by genotypes, in peripheral blood mononuclear cells of healthy subjects. We found 27 SNPs in 11 lncRNA genes associated with endemic PF (p < .05 without overlapping with protein‐coding genes). Among them, the LINC‐PINT SNP rs10228040*A (OR = 1.47, p = .012) was also associated with increased susceptibility for sporadic PF (OR = 2.28, p = .002). Moreover, the A+ carriers of LY86‐AS1*rs12192707 mark lowest LY86‐AS1 RNA levels, which might be associated with a decreasing autoimmune response. Our results suggest a critical role of lncRNA variants in immunopathogenesis of both PF endemic and sporadic forms.


  • Open Access

    Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort

    by Dirk-Jan van Beek, Helena M. Verkooijen, Sjoerd Nell, Bert A. Bonsing, Casper H. van Eijck, Harry van Goor, Frederik J.H. Hoogwater, Elisabeth J.M. Nieveen van Dijkum, Geert Kazemier, Cornelis H.C. Dejong, et al.

    Background: Pancreatic neuroendocrine tumors (pNETs) have a high prevalence in patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision-making. We assessed reliability and agreement of radiological and pathological tumor size in a population-based cohort of patients with MEN1-related pNETs. Methods: Patients were selected from the Dutch MEN1 database if they had undergone a resection for a pNET between 2003 and 2018. Radiological (MRI, CT, and endoscopic ultrasonography [EUS]) and pathological tumor size were collected from patient records. Measures of agreement (Bland-Altman plots with limits of agreement [LoA] and absolute agreement) and reliability (intraclass correlation coefficients [ICC] and unweighted kappa) were calculated for continuous and categorized (< or ≥2 cm) pNET size. Results: In 73 included patients, the median radiological and pathological tumor sizes measured were 22 (3–160) and 21 (4–200) mm, respectively. Mean bias between radiological and pathological tumor size was −0.2 mm and LoA ranged from −12.9 to 12.6 mm. For the subgroups of MRI, CT, and EUS, LoA of radiological and pathological tumor size ranged from −9.6 to 10.9, −15.9 to 15.8, and −13.9 to 11.0, respectively. ICCs for the overall cohort, MRI, CT, and EUS were 0.80, 0.86, 0.75, and 0.76, respectively. Based on the 2 cm criterion, agreement was 81.5%; hence, 12 patients (18.5%) were classified differently between imaging and pathology. Absolute agreement and kappa values of MRI, CT, and EUS were 88.6, 85.7, and 75.0%, and 0.77, 0.71, and 0.50, respectively. Conclusion: Within a population-based cohort, MEN1-related pNET size was not systematically over- or underestimated on preoperative imaging. Based on agreement and reliability measures, MRI is the preferred imaging modality.